alpha7 nicotinic acetylcholine receptor positive allosteric modulators (Proximagen)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug Namealpha7 nicotinic acetylcholine receptor positive allosteric modulators (Proximagen)
Drug Alias Namealpha7 nicotinic acetylcholine receptor positive allosteric modulators (GlaxoSmithKline)PheTQS
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeuronal acetylcholine receptor protein alpha-7 subunit agonists
TargetsNeuronal acetylcholine receptor protein alpha-7 subunit
Therapy Area/IndicationsCentral Nervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesProximagen Group plcGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsCentral Nervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A